The 5 drugs tracked here made ≈$25.0B of Roche’s 2025 revenue (34%) and lose US exclusivity by 2034. Since 2023, Roche has closed 4 acquisitions of $1B or more, worth $13.2B in total.
Bars are each drug's 2025 sales as a share of Roche’s total revenue (≈$74.1B). Group sales CHF 61.5B, including Diagnostics. Only drugs tracked here are counted, so full exposure can be higher. Tap a bar for the drug's page.
| Closed | Company bought | Value | Area | What it brought | At closing |
|---|---|---|---|---|---|
| Dec 2023 | TelavantRoche, October 2023 · Roche Annual Report 2023 | $7.1B | Immunology | US and Japan rights to afimkibart (RVT-3101), an antibody for ulcerative colitis and Crohn's diseasePlus a near-term $0.15B milestone. | Pipeline only |
| Jan 2024 | Carmot TherapeuticsRoche, December 2023 · Roche Finance Report 2024 | $2.7B | Cardiometabolic | Three obesity and diabetes drugs in clinical trialsUpfront payment; up to $0.4B more in milestones. | Pipeline only |
| Jan 2025 | Poseida TherapeuticsRoche, November 2024 · Roche Finance Report 2025 | $1.0B | Oncology | Off-the-shelf CAR-T therapies for blood cancers and autoimmune diseasePlus a CVR worth up to $0.5B. | Pipeline only |
| Oct 2025 | 89bioRoche, September 2025 · Roche, October 2025 | $2.4B | Cardiometabolic | Pegozafermin, a Phase 3 drug for MASH, a fatty liver diseasePlus a CVR worth up to $1.1B. | Pipeline only |
| 4 counted | $13.2B | ||||
Acquisitions of whole companies closed since January 2023 with a headline price of $1B or more. Values are the price Roche announced, excluding milestone payments unless noted. Licensing deals are not included. Compare all 65 deals →
| Area | At risk by 2037 | Acquisitions since 2023 |
|---|---|---|
| Immunology | ≈$3.7B | $7.1B |
| Oncology | ≈$7.9B | $1.0B |
| Neuroscience | ≈$8.4B | – |
| Cardiometabolic | – | $5.1B |
| Other | ≈$4.9B | – |
Roche has the most revenue at risk in neuroscience, but has spent the most on acquisitions in immunology. At risk is 2025 sales of tracked drugs losing US exclusivity by 2037; acquisitions are the headline value of counted deals closed since 2023.
The two figures measure different things. Revenue at risk is what the drugs earned in 2025. A deal's value is what Roche paid, not the sales it will bring in. None of the companies it bought had an approved product at closing, so any sales from them are years away and may never arrive. So this page shows the figures side by side rather than claiming how much of the gap the deals fill.
Revenue: Roche FY2025. Drug sales and dates are sourced on each drug's page; each deal links to Roche’s announcement or filing in the table above.
See all 63 drugs on the patent cliff →